BioNTech SE Sponsored ADR (BNTX) vs Royalty Pharma PLC (RPRX)

BioNTech SE Sponsored ADR and Royalty Pharma PLC are both Biotechnology companies. Royalty Pharma PLC is the larger, with a market value of $34.3B against $22.7B — 1.5× the size. BioNTech SE Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Royalty Pharma PLC trades at 42.3×. Royalty Pharma PLC grew revenue faster over the last twelve months: 10.0% against −3.33%. Royalty Pharma PLC has the higher net margin (32.0% vs −65.8%) and the higher return on invested capital (5.28% vs −38.4%). Across the 20 metrics below, Royalty Pharma PLC leads on 13 and BioNTech SE Sponsored ADR on 7.

Valuation

Metric BNTX RPRX Biotechnology median
P/E n/m 42.27 8.50
P/S 7.35 10.76 9.71
P/B 1.07 2.79 2.13
Price to free cash flow 44.31 20.82 20.82
EV/EBITDA n/m 22.88 0.64
EV/Sales 1.78 13.96 9.21
Earnings yield (8.94%) 2.37% (33.15%)
Free cash flow yield 2.26% 4.80% (25.50%)

Profitability

Metric BNTX RPRX Biotechnology median
Gross margin 75.24% 100.00% 65.16%
Operating margin (77.94%) 59.61% 0.00%
Net margin (65.75%) 32.02% 0.00%
Free cash flow margin 16.58% 51.66% 0.00%
Return on equity (9.53%) 8.42% (56.36%)
Return on assets (8.24%) 4.26% (48.04%)
Return on invested capital (38.39%) 5.28% 0.00%

Growth

Metric BNTX RPRX Biotechnology median
Revenue growth (TTM) (3.33%) 10.01% 6.02%
EPS growth (last fiscal year) (77.33%) (5.52%) 30.26%
Revenue growth, 5-year CAGR 42.58% 2.30% 9.41%
Net income growth, 5-year CAGR 0.00% (4.59%) 0.00%

Health

Metric BNTX RPRX Biotechnology median
Debt to equity 0.02 0.92 0.00
Current ratio 7.85 2.80 4.72
Net debt to EBITDA 14.29 5.22 0.96

Dividend

Metric BNTX RPRX Biotechnology median
Dividend yield — 1.51% 0.09%
Payout ratio — 0.64 —

Size

Metric BNTX RPRX Biotechnology median
Market cap 22.66b 34.28b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack